ABM-1310
As of the edition of 20 October 2026, ABM-1310 is a small molecule: stopped in 2024; acts on BRAF.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 3, 3 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Digestive system; Hormones; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of ABM-1310.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| BRAF | Serine/threonine-protein kinase B-raf | P15056 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 0 | 0 | 3 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| ABM Therapeutics | Lead sponsor of trials | 2020 to now |
| ABM Therapeutics Shanghai | Lead sponsor of trials | 2022 to now |